MiMedx Group (NASDAQ:MDXG – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.
Other analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st. Craig Hallum decreased their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $12.00.
Get Our Latest Analysis on MiMedx Group
MiMedx Group Stock Performance
Institutional Trading of MiMedx Group
A number of hedge funds have recently bought and sold shares of the stock. AJOVista LLC acquired a new stake in MiMedx Group in the 4th quarter valued at about $25,000. Headlands Technologies LLC acquired a new stake in MiMedx Group in the 1st quarter valued at about $27,000. Loudon Investment Management LLC acquired a new stake in MiMedx Group in the 4th quarter valued at about $105,000. Entropy Technologies LP acquired a new stake in MiMedx Group in the 1st quarter valued at about $99,000. Finally, Raymond James & Associates acquired a new stake in MiMedx Group in the 4th quarter valued at about $114,000. 79.15% of the stock is owned by institutional investors.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
See Also
- Five stocks we like better than MiMedx Group
- Using the MarketBeat Dividend Tax Calculator
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- How Investors Can Find the Best Cheap Dividend Stocks
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- Dividend Capture Strategy: What You Need to Know
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.